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Abstract: Current strategies for the treatment of hereditary angio-
edema (HAE) include targeted inhibition or antagonism of the
contact system, which is dysregulated in HAE patients by a C1
esterase inhibitor deficiency. Ecallantide, a plasma kallikrein inhib-
itor, and icatibant, a selective bradykinin-2 receptor antagonist, have
recently been evaluated in clinical studies for the treatment of acute
HAE attacks. Both drugs have demonstrated evidence of efficacy
and safety in treating acute HAE episodes, with ecallantide approved
for use in the United States and icatibant approved for use in Europe.
As therapeutic options for HAE expand for both for prophylactic
and acute treatment strategies, a number of patient-specific and
drug-specific factors have emerged as important considerations
when developing individualized HAE management plans. Optimi-
zation of HAE therapy will require further integration of new
therapies into the current treatment paradigm.
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Hereditary angioedema (HAE) is a rare genetic conditioncaused by C1 esterase inhibitor (C1INH) deficiency and
marked by episodic cutaneous, intestinal, or laryngeal swell-
ing. HAE symptom frequency and severity is highly variable,
but the unpredictable attacks of angioedema are frequently
disabling and occasionally fatal. Historically, treatment op-
tions for HAE have been extremely limited in many parts of
the world. Therapeutic agents recently developed for the
acute treatment of HAE attacks can be categorized into 2
general groups: protein replacement therapies and medica-
tions targeted at specific single components of the contact
pathway (Fig. 1). C1INH replacement therapy is discussed
elsewhere in the supplement. Reviewed here are 2 HAE
therapies, ecallantide and icatibant, that target specific ele-
ments of the contact pathway.
Tissue angioedema episodes associated with C1INH
deficiency are mediated by dysregulation of the contact sys-
tem, ultimately leading to overproduction of bradykinin.1
C1INH has numerous inhibitory functions within the contact
pathway and within the complement and fibrinolytic sys-
tems.2 Within the contact or kinin system, which is most
relevant to the pathophysiology of the clinical angioedema of
HAE, the most important inhibitory effects of C1INH are on
Factor XIIa and kallikrein. In the absence of sufficient
C1INH, factor XIIa effectively initiates a cascade leading to
the local tissue production of bradykinin.3 Factor XIIa ac-
complishes this by converting prekallikrein to kallikrein and
also by activating a highly efficient autoactivation cycle,
whereby factor XIIa acts on factor XII to produce additional
factor XIIa.4 This cycle efficiently up-regulates kallikrein
production. Because C1INH also acts as a major inhibitor of
kallikrein activity, inadequate C1INH concentrations permit
unregulated kallikrein cleavage of high-molecular-weight
kininogen (HMWK) to produce bradykinin. Data from nu-
merous in vitro, animal, and human studies strongly support
bradykinin as the major mediator of tissue angioedema in
individuals with HAE.5–7
The critical reactions of the contact pathway leading to
HAE angioedema symptoms (factor XIIa 3 kallikrein 3
bradykinin) occur locally at the surface of endothelial cells.8
The endothelial cell membrane appears to be a naturally
occurring location for bradykinin production because Factor
XII binds to a complex of the urokinase plasminogen activa-
tor receptor and cytokeratin 1 expressed on endothelial cell
surfaces.9 Circulating HMWK–kallikrein complexes prefer-
entially bind to the receptor for the globular heads of C1q and
cytokeratin 1 on the endothelial cell surface.10 Localization of
these components facilitates production of bradykinin, which
then interacts with the bradykinin-2 receptor (B2R), also
located on the endothelial cell surface.11 Activation of B2R
results in increased vascular permeability; release of associ-
ated nitric oxide and prostaglandin E, which augment vaso-
dilatation; and resulting extravasation of fluid into subcuta-
neous tissue spaces (ie, angioedema).6,12 Thus, while C1INH
acts at multiple sites to regulate the contact cascade, kal-
likrein and bradykinin are the critically dysregulated compo-
nents leading to the clinical symptomatology of HAE. As a
result, recent clinical investigations have included consider-
able focus on targeted therapies that 1) specifically inhibit
kallikrein activity, thereby down-regulating bradykinin pro-
duction, or 2) block bradykinin-mediated vascular effects,
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thereby preventing the endothelial permeability that ulti-
mately leads to tissue swelling.
KALLIKREIN INHIBITION
Ecallantide (Kalbitor, Dyax, Cambridge, MA) is a 60-
amino-acid protein that was identified by phage-display tech-
nology, a process that allows large libraries of proteins to be
screened and selected for specific functions or binding activ-
ity. Ecallantide (also known as DX-88), selected for its high
affinity and specificity for human plasma kallikrein, inhibits
kallikrein activity and thereby prevents bradykinin synthesis.
Ecallantide is produced in a Pichia pastoris expression sys-
tem, and though administered intravenously in early clinical
development, the 30 mg dose used in Phase III studies is
currently formulated for subcutaneous administration via 3
individual 1-mL injections. The plasma half-life of ecallan-
tide is 2 hours.13
After preclinical and early clinical development, 2
Phase III clinical studies were performed to investigate ecal-
lantide therapy for the treatment of acute HAE episodes. The
2 studies, termed EDEMA3 and EDEMA4 (Evaluation of
DX-88 Effects inMitigating Angioedema), were conducted as
randomized, double-blind, placebo-controlled trials of treat-
ment for cutaneous, abdominal, and laryngeal angioedema
attacks in subjects with Type I or Type II HAE. The EDEMA
studies used 2 unique patient-reported outcome measures
with each having been specifically designed and validated by
the study sponsor for the evaluation of HAE symptoms.14 The
Treatment Outcome Score (TOS) is a three-component tool
that includes evaluation of anatomic sites affected, symptom
severity, and change in symptoms over time. The TOS
reflects overall improvement or worsening relative to baseline
based on these patient-reported variables, with a possible
range of 100 (significant improvement) to 100 (signifi-
cant worsening), where 0 represents no change. Thus, an
increased TOS indicates clinical improvement. The Mean
Symptom Complex Score (MSCS) is a similar though
somewhat less complex patient-reported outcome mea-
surement. The MSCS is based on 2 factors: site(s) of
swelling and symptom severity. The MSCS score range is
0 (no symptoms) to 3 (severe symptoms), so that lower
MSCS represents clinical improvement. These validated
measurement tools were useful and effective for regulatory
purposes, though not particularly intuitive to clinicians or
patients reviewing the study data.
EDEMA3 included 72 randomized subjects experienc-
ing acute HAE attacks and had a primary end point of
symptom improvement as measured by TOS at 4 hours after
drug administration. Data from 69 subjects could be analyzed
for this time point and showed a significant improvement for
the ecallantide-treated group compared with placebo (mean
TOS 63 vs 36, P  0.045). At 24 hours after the dose, this
treatment effect was maintained, with a statistically signifi-
cant improvement for ecallantide over placebo (P  0.02).15
EDEMA4 followed a study design very similar to
EDEMA3, although the primary outcome was shifted to the
change in patient-reported MSCS at 4 hours after drug ad-
ministration. Ninety-six subjects with acute HAE symptoms
were randomized to ecallantide or placebo, with results again
demonstrating superior treatment outcomes for ecallantide
compared with placebo. At 4 hours, 89 subjects had evaluable
data, which showed a mean change in MSCS of 0.8 for
ecallantide versus 0.4 for placebo (P  0.01; Fig. 2) This
treatment effect was again evident at 24 hours after the dose
with a greater mean reduction in MSCS for ecallantide versus
placebo (1.5 vs 1.1, P  0.04).15 Thus, these 2 similar
FIGURE 1. Therapy for HAE is directed at controlling the
dysregulated activity of kallikrein and bradykinin that is re-
sponsible for the clinical symptoms of HAE. The hatched bar
represents the inhibitory activity of C1INH, the orange bar the
inhibitor activity of ecallantide, and the black X the receptor
antagonism of icatibant. Source: Kaplan AP, Joseph K. The bra-
dykinin-forming cascade and its role in hereditary angioedema.
Ann Allergy Asthma Immunol. 2010;104:193–204.
FIGURE 2. The randomized, double-blind, placebo-con-
trolled EDEMA4 study demonstrated a statistically significant
improvement in the Mean Symptom Complex Score (MSCS)
at 4 hours after treatment with ecallantide compared with
placebo for acute HAE episodes. Source: Developed from
data provided in Table 7 of US Food and Drug Administra-
tion (www.fda.gov/ohrms/dockets/AC/09/briefing/2009-
4413b1-03-Dyax.pdf).
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Phase III studies, which included 143 unique HAE patients,
showed consistent results demonstrating the efficacy of ecal-
lantide for acute HAE attacks.
With regard to safety, ecallantide was generally well-
tolerated, with most reported side effects of mild severity and
occurring with similar frequency in both drug and placebo
groups. These included symptoms commonly seen with HAE
attacks (abdominal pain, nausea) but also upper respiratory
tract infections, headache, and fatigue.15 However, through-
out the course of the ecallantide clinical development pro-
gram, 10 of 255 subjects developed systemic hypersensitivity
reactions consistent with anaphylaxis. All reactions occurred
with 60 minutes of dosing and all patients recovered com-
pletely without sequelae after appropriate medical treat-
ment.16 To date, the cause of these reactions is unclear, as no
specific patterns or predictive risk factors have been identi-
fied. Anti-ecallantide antibodies have been detected in 12.9%
of study subjects, including anti-ecallantide IgE in 2.1%;
however, anti-drug antibodies do not seem to be strongly
associated with hypersensitivity reactions.15,16 Further, some
subjects experiencing anaphylaxis were cautiously rechal-
lenged after skin testing and tolerated ecallantide without
systemic reaction. In contrast, one patient clearly had a
reproducible acute anaphylactic reaction with a rechallenge
procedure.16
On the basis of the efficacy and safety data from
EDEMA3 and EDEMA4, ecallantide was approved by the
FDA in December 2009 for the treatment of acute attacks of
HAE. The concern for hypersensitivity reactions prompted a
boxed warning highlighting the potential risk of anaphylaxis
and the need for the drug to be administered by a health care
professional. Ecallantide is commercially available in the
United States with a required Phase IV safety study instituted
to track and investigate any additional occurrences of dose-
related anaphylaxis.
BRADYKININ RECEPTOR ANTAGONISM
Given the role of bradykinin as the principal mediator
of vascular permeability and tissue swelling in HAE, targeted
blockade of bradykinin effects is a rational strategy for
treatment. Icatibant (Firazyr, Shire HGT, Basingstoke, UK) is
a second-generation BR2 receptor antagonist that has been
investigated for the treatment of acute HAE attacks. Icatibant
is a synthetic decapeptide with a structure similar to brady-
kinin but containing 5 nonproteinogenic amino acids.
Thereby, it functions as a highly potent, selective, competi-
tive antagonist at the B2R site and is not degraded by major
bradykinin-metabolizing enzymes, so that it is more stable
than bradykinin. Icatibant is formulated for subcutaneous
administration as a single 3-mL (30-mg) injection and has a
terminal half-life of 1 to 2 hours.17
Two Phase III trials investigating the efficacy and
safety of icatibant in treating acute cutaneous, abdominal, and
laryngeal HAE attacks have been completed. The studies,
known as FAST 1 and FAST 2 (For Angioedema Subcuta-
neous Treatment 1 and 2) were both randomized, double-
blind, controlled trials with nearly identical study designs,
objectives, and endpoints. However, the FAST 1 study
(JE409 #2103), conducted in North America, Argentina, and
Australia, was placebo-controlled, whereas the FAST 2 study
(JE409 #2102), conducted in Europe and Israel, used tranex-
amic acid treatment as the control/comparator. The primary
endpoint for both Phase III studies was median time to onset
of relief as determined by patient-reported visual analogue
scales (VAS). The standardized VAS tool is a 100-mm scale
ranging from 0 “no symptoms” to 100 “worst possible symp-
toms.” Onset of symptom relief was defined as an absolute
reduction from predose VAS of 20 mm for predose scores
of 30–50 or 30 for predose scores 50. Initial onset of
relief was determined retrospectively after the subject re-
ported 3 consecutive time points with symptom relief.18
FAST 1 included 64 treated subjects, with 56 subjects
randomized and 8 subjects treated with open-label icatibant
for laryngeal edema. Median time to onset of symptom relief
was 2.5 hours for icatibant compared with 4.6 hours for
placebo (P  0.142). This difference in the primary end
point was not statistically significant, although a number of
secondary endpoints strongly supported significant im-
provement in the icatibant group compared with placebo.
These included median time to regression (start of im-
provement) of symptoms (0.8 vs 16.9 hours, P  0.001
favoring icatibant) and median time to overall patient
improvement by physician assessment (1.0 vs 5.7 hours,
P  0.001 favoring icatibant).18
FAST 2 enrolled 77 subjects with 74 randomized and 3
subjects treated for laryngeal edema with open-label drug.
Consistent with the effect observed in FAST 1, median time
to onset of symptom of relief was 2.0 hours for icatibant but
12 hours for the tranexamic acid comparator arm (P 
0.001). Statistically significant results were observed for
secondary endpoints as well, supporting the superior efficacy
of icatibant compared with tranexamic acid for the treatment
of acute HAE attacks.18
No serious adverse events or systemic hypersensitivity
reactions were identified in the clinical studies of icatibant.
Reported adverse drug effects were generally mild, with the
most common being local symptoms at the subcutaneous
injection site. Injection site reactions were reported in most
patients receiving icatibant and included symptoms of ery-
thema, burning, pruritis, and swelling. Such reactions were
self-limited, lasting 10 minutes to a few hours, and did not
seem to be associated with any risk of more serious reactions.
No subjects withdrew from the studies because of these local
reactions. Icatibant does not seem to be immunogenic, al-
though no reliable antibody test exists.18
Because of the primary endpoint outcome in FAST 1,
icatibant failed to obtain FDA approval for use in the United
States. Factors contributing to the FAST 1 study outcome are
not entirely clear, although a surprisingly robust placebo
effect was evident. Additionally, it has been proposed that the
analytical approach (responder analysis) likely contributed to
the lack of statistical significance. An alternative analysis,
examining change from baseline at the 4- and 12-hour time
points, did demonstrate the statistical superiority of icatibant
at both timepoints.18 On the basis of the clinical efficacy and
safety data of FAST 1 and FAST 2 (Fig. 3), icatibant was
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approved for the treatment of acute HAE by the European
Medicines Agency in July 2008 and is currently prescribed in
several European countries and Brazil. An additional Phase
III study of icatibant for acute treatment of HAE was initiated




The recent development of multiple therapies for the
treatment of HAE has increased the availability of effective
medications. In some instances, individuals with HAE have
unprecedented therapeutic options. These advances provide op-
portunities to optimize the medical care and quality of life for
HAE patients, but are accompanied by both practical and
societal challenges. Providers treating HAE will need to
consider a number of important factors when consulting with
and managing the treatment of individual patients.
Because of the wide variability in symptoms for indi-
vidual HAE patients, treatment strategies will ideally take
into account a number of patient-specific factors.19 Clearly,
these include the frequency and severity of angioedema
symptoms, which may principally determine whether regular
prophylactic therapy or intermittent on-demand acute therapy
is most beneficial. Rapidity of attack progression and access
to acute medical care may also play a role when considering
long-term prophylactic versus as-needed therapy. The fre-
quency of variability in the therapeutic response to new
agents and their adverse effects have not yet been fully
determined. Variability is evident in individual responses to
prophylactic C1INH therapy,20 and adverse effects are well
demonstrated by the rare hypersensitivity reactions to ecal-
lantide.21 Research efforts to better define or predict this
variability will improve the tailoring of therapy to individual
patients.
Drug-specific features will also be important in thera-
peutic decision-making. Though study protocol differences
make direct comparisons of data difficult, the C1INH prod-
ucts, ecallantide and icatibant seem to have comparable
treatment effects,15,18,22,23 so that clinical efficacy does not
seem to be a strong factor for distinguishing among them.
With regard to safety, plasma C1INH products have a long
and extensive history of safe use despite a theoretical risk of
transmission of infectious agents. Some concern exists for
allergic reactions to recombinant C1INH and ecallantide, but
recent study data demonstrate this to be a greater concern for
ecallantide, with its small but real risk of hypersensitivity
reactions.15,24 Icatibant appears to have an excellent safety
profile to date, although clinical experience is somewhat
limited. Route of drug administration is currently a distin-
guishing feature. C1INH products are presently approved
only for intravenous use, which may present logistical chal-
lenges in some situations. There is considerable interest in the
use of C1INH products subcutaneously; however, at present
this remains in clinical development. Consequently, because
of the unpredictability of HAE attacks, patients may face
challenges in rapidly accessing IV products through clinics or
emergency departments. Self-infusion programs and infra-
FIGURE 3. Mean posttreatment VAS scores over time for icatibant and comparator treatment of acute HAE episodes in the
randomized, double-blind FAST 1 and FAST 2 studies. Source: European Medicines Agency (http://www.ema.europa.eu/
humandocs/PDFs/EPAR/firazyr/H-899-en6.pdf).
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structure are likely to improve this situation, though not every
patient will be comfortable with this approach. Subcutaneous
products may be attractive for many patients, but the risk of
hypersensitivity reactions with ecallantide likely precludes
home self-administration at present. Finally, medication costs
will be a factor for most HAE patients and health care
organizations, representing a difficult issue that each region
or country must address. Drug development for rare condi-
tions is an expensive endeavor, and while medication policies
and pricing vary nationally, health care expenses for serious,
chronic medical conditions are an important societal issue in
most communities. Thus, with new therapies comes the
challenge of devising individualized management plans for
each patient that will reduce the morbidity and disability of
HAE, minimize treatment complications, and remain sustain-
able for long-term management.
In summary, major advances in therapy for HAE have
occurred in recent years, with an increase in effective treat-
ment options for this rare and often devastating condition.
Though patients and providers are still determining how to
optimally incorporate newer medications into HAE manage-
ment plans, a number of important treatment goals may
eventually be realized. With proper training, home treatment
of angioedema attacks may be possible with self-infused
C1INH products or eventually with subcutaneous icatibant or
ecallantide. Based on previous studies, such self-treatment is
expected to reduce the duration of attacks compared with
hospital treatment and to minimize the detrimental impact on
patient lives.25,26 Long-term prophylactic C1INH therapy and
effective available acute therapy may ultimately reduce re-
quirements for attenuated androgens in some patients,
thereby reducing the toxicities and complications occasion-
ally associated with androgens.27 Most importantly, these
therapies provide reliable life-saving and life-changing relief
from the unpredictable attacks suffered by HAE patients
around the world.
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